NCT01267071View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

June 14, 2010

Primary Completion Date

September 1, 2010

Study Completion Date

September 1, 2010

Conditions
Gastroparesis
Interventions
DRUG

A

GSK962040 (50 mg, SD, oral)

DRUG

B

14C GSK962040 (100 μg, SD, iv)

Trial Locations (1)

NG11 6JS

GSK Investigational Site, Nottingham

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01267071 - A Study to Evaluate the Pharmacokinetics and Absolute Bioavailability of GSK962040 Given as an Oral Dose Simultaneously With an Intravenous Microtracer Dose of [14C]-GSK962040 in Healthy Volunteers | Biotech Hunter | Biotech Hunter